Crossmark

421 A first-in-human (FIH) phase I/IIa clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT

Crossref DOI link: https://doi.org/10.1136/jitc-2021-SITC2021.421

Published Online: 2021-11-10

Published Print: 2021-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Linch, Mark

Papai, Zsuzsanna

Takacs, Istvan

Imedio, Esteban Rodrigo

Kühnle, Marie-Cristine

Derhovanessian, Evelyna

Vogler, Isabel

Renken, Stephanie

Graham, Philippa

Sahin, Ugur

Türeci, Özlem
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04382898 at ClinicalTrials.gov

Documents that mention this clinical trial

421 A first-in-human (FIH) phase I/IIa clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT
https://doi.org/10.1136/jitc-2021-sitc2021.421

Shared epitopes create safety and efficacy concerns in several cancer vaccines
https://doi.org/10.1136/jitc-2025-012217

Document is current

Any future updates will be listed below